Patents by Inventor Noam PILPEL

Noam PILPEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC RECEPTORS AND USES THEREOF
    Publication number: 20240207315
    Abstract: Chimeric receptors are provided. Accordingly, there is provided a chimeric receptor comprising an extracellular binding domain and a heterologous amino acid sequence capable of recruiting a co-receptor comprising an intracellular signaling domain, such that upon binding of the extracellular binding domain to its target the signaling is transmitted in a cell expressing the chimeric receptor and the co-receptor. Also provided are protein complexes comprising the receptors, cells expressing same and uses thereof.
    Type: Application
    Filed: December 27, 2023
    Publication date: June 27, 2024
    Applicant: Gilboa Therapeutics LTD
    Inventors: Noam PILPEL, Peleg RIDER, Yaron CARMI, Shahar DOTAN, Diana RASOULOUNIRIANA, Hana SHPILT
  • p21 mRNA target areas for silencing
    Patent number: 11981896
    Abstract: Compositions of matter comprising RNA silencing molecules capable of mediating cleavage of p21 mRNA are disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Grant
    Filed: June 28, 2023
    Date of Patent: May 14, 2024
    Assignee: 1E Therapeutics Ltd.
    Inventors: Noam Pilpel, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • P21 MRNA TARGETING DNAZYMES
    Publication number: 20240076671
    Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42, 45-48, 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Application
    Filed: September 28, 2023
    Publication date: March 7, 2024
    Applicant: Rehovot
    Inventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • P21 mRNA targeting DNAzymes
    Patent number: 11879140
    Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42, 45-48, 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Grant
    Filed: June 28, 2023
    Date of Patent: January 23, 2024
    Assignee: 1E THERAPEUTICS LTD.
    Inventors: Noam Pilpel, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • P21 MRNA TARGETING DNAZYMES
    Publication number: 20230365952
    Abstract: A composition of matter comprising a DNAzyme molecule capable of mediating cleavage of p21 mRNA corresponding to SEQ ID NO: 1, wherein said DNAzyme molecule comprises a nucleic acid sequence at least 80% identical to the nucleic acid sequence set forth in any one of SEQ ID NOs: 23, 29, 33-38, 40, 42. 45-48. 53-60, 63-65, 69-74 or 78, is disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Application
    Filed: June 28, 2023
    Publication date: November 16, 2023
    Applicant: 1E Therapeutics Ltd.
    Inventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • P21 MRNA TARGET AREAS FOR SILENCING
    Publication number: 20230357771
    Abstract: Compositions of matter comprising RNA silencing molecules capable of mediating cleavage of p21 mRNA are disclosed. Methods of eradicating senescent cells or cancer cells, as well as methods of treating senescence-associated diseases or disorders, cancer, and fibrotic diseases and disorders are also disclosed.
    Type: Application
    Filed: June 28, 2023
    Publication date: November 9, 2023
    Applicant: 1E Therapeutics Ltd.
    Inventors: NOAM PILPEL, Yossi Ovadya, Dina Raichlin, Etti Katz-Kadosh, Alaa Knany, Ella Gillis, Noam Borovsky, Anastasia Shapiro, Ido Bachelet
  • METHOD OF PROMOTING HAIR GROWTH
    Publication number: 20180345047
    Abstract: A method of promoting hair growth or reducing hair loss in a subject is disclosed. The method comprises contacting the scalp and skin region in which there is desire for hair growth of the subject with an effective amount of at least one agent which down-regulates an activity and/or an amount of a protein selected from the group consisting of p21, Bcl-xL and Bcl-w. Compositions capable of same are also disclosed.
    Type: Application
    Filed: February 25, 2016
    Publication date: December 6, 2018
    Inventors: Valery KRIZHANOVSKY, Reut YOSEF, Noam PILPEL, Ittai BEN-PORATH, Liat DASSA, Ronit AMIEL-TOKARSKY
  • AGENTS FOR DOWNREGULATION OF THE ACTIVITY AND/OR AMOUNT OF BCL-XL AND/OR BCL-W
    Publication number: 20160122758
    Abstract: A method of treating an inflammatory or fibrotic disease in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which down-regulates an activity and/or an amount of Bcl-xL and/or Bcl-w and/or p21, with the proviso that the inflammatory disease is not cancer.
    Type: Application
    Filed: April 13, 2014
    Publication date: May 5, 2016
    Inventors: Valery KRIZHANOVSKY, Noam PILPEL, Reut YOSEF